Key practice points in the management of fibromyalgia

American Family Physician

Volumn 76, Issue 2, 2007, Pages 195-

  Huynh, Christine N ^a   Yanni, Leanne M ^a   Morgan, Laura A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANXIETY; CHRONIC FATIGUE SYNDROME; COGNITIVE THERAPY; DEPRESSION; EDITORIAL; EVIDENCE BASED MEDICINE; FIBROMYALGIA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IRRITABLE COLON; NOCICEPTION; PHYSICIAN; RESTLESS LEGS SYNDROME; SCREENING; SLEEP APNEA SYNDROME; TEMPOROMANDIBULAR JOINT DISORDER;

DISEASE MANAGEMENT; FIBROMYALGIA; HUMANS; PRIMARY HEALTH CARE; SELF CARE;

EID: 34547146426     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (23)

1. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95.
2. Burckhardt CS, Goldenberg DL. Guideline for the management of fibromyalgia syndrome pain in adults and children. Clinical practice guideline no. 4. Glenview, Ill.: American Pain Society, 2005.
3. Chakrabarty S, Zoorob R. Fibromyalgia. Am Fam Physician 2007;76:247-54.
4. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
5. Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned? Arch Intern Med 1999;159: 777-85.
6. Adler GK, Geenen R. Hypothalamic-pituitary-adrenal and autonomic nervous system functioning in fibromyalgia. Rheum Dis Clin North Am 2005;31:187-202, xi.
7. Moldofsky H, Warsh JJ. Plasma tryptophan and musculoskeletal pain in non-articular rheumatism ("fibrositis syndrome"). Pain 1978;5:65-71.
8. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992;19:90-4.
9. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-6.
10. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7.
11. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lowe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007;146:317-25.
12. Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997;12:439-45.
13. Hening WA, Allen RP, Thanner S, Washburn T, Heckler D, Walters AS, et al. The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. Sleep Med 2003;4:137-41.
14. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999;131:485-91.
15. Nilsson IM, List T, Drangsholt M. The reliability and validity of self-reported temporomandibular disorder pain in adolescents. J Orofac Pain 2006;20:138-44.
16. John MT, Dworkin SF, Mancl LA. Reliability of clinical temporomandibular disorder diagnoses. Pain 2005; 118:61-9.
17. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-33.
18. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain 1992;50:133-49.
19. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the Brief Pain Inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309-18.
20. Holdcraft LC, Assefi N, Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:667-83.
21. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr, et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005;116:276-88.
22. Vera-Portocarrero LP, Zhang ET, King T, Ossipov MH, Venderah TW, Lai J, et al. Spinal NK-1 receptor expressing neurons mediate opioid-induced hyperalgesia and antinociceptive tolerance via activation of descending pathways. Pain 2007;129:35-45.
23. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006;7:43-8.